Discovery of a potent Gilteritinib-based FLT3-PROTAC degrader for the treatment of Acute myeloid leukemia
Bioorganic Chemistry · 2024
DOI: 10.1016/j.bioorg.2024.107477 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2024. Verfasst von Lei Ye und 10 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR C…. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Antineoplastic Agents, Pyrazines. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Fms-like tyrosine receptor kinase 3 (FLT3) proteolysis targeting chimeras (PROTACs) emerge as a promising approach to overcome the limitations of FLT3 inhibitors, while the development of orally bioavailable FLT3-PROTACs faces great challenges. Here, we report the rational design and evaluation of a series of Gilteritinib-based FLT3-PROTACs. Among them, B3-2 exhibited the strongest antiproliferative activity against FLT3-ITD mutant AML cells, and significantly induced FLT3-ITD protein degradation. Mechanistic investigations demonstrated that B3-2 induced FLT3-ITD degradation in a ubiquitin-proteasome-dependent manner. More importantly, B3-2 exhibited an oral bioavailability of 5.65%, and oral administration of B3-2 showed good antitumor activity in MV-4-11 xenograft models. Furthermore, B3-2 showed strong antiproliferative activity against FLT3 resistant mutations, highlighting its potential in overcoming drug resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR China.
- Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR China; National Key Laboratory on Technologies for Chinese Medicine Pha…
Zitieren
APA
Ye, L., Cui, Z., Sun, Y., Zhou, H., Rong, Q., Wang, D., Jin, J., Zhang, Q., Kang, D., Hu, L., & Wang, J. (2024). Discovery of a potent Gilteritinib-based FLT3-PROTAC degrader for the treatment of Acute myeloid leukemia. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2024.107477
Vancouver
Ye L, Cui Z, Sun Y, Zhou H, Rong Q, Wang D, et al. Discovery of a potent Gilteritinib-based FLT3-PROTAC degrader for the treatment of Acute myeloid leukemia. Bioorganic Chemistry. 2024. doi:10.1016/j.bioorg.2024.107477
BibTeX
@article{Ye2024,
author = {Ye, Lei and Cui, Zhenzhen and Sun, Yu and Zhou, Haikun and Rong, Quanjin and Wang, Dan and Jin, Jiaming and Zhang, Qijian and Kang, Di and Hu, Lihong and Wang, Junwei},
title = {Discovery of a potent Gilteritinib-based FLT3-PROTAC degrader for the treatment of Acute myeloid leukemia},
journal = {Bioorganic Chemistry},
year = {2024},
doi = {10.1016/j.bioorg.2024.107477}
}
EUVIMED